World Health Organization site
Skip Navigation Links

Please fill this short user satisfaction survey


Main
Note: This record shows only 22 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register.
Register: ClinicalTrials.gov
Last refreshed on: 19 February 2015
Main ID:  NCT00573326
Date of registration: 13/12/2007
Prospective Registration: Yes
Primary sponsor: Azienda Ospedaliera Universitaria Policlinico
Public title: Low-Dose Oral Imatinib for Scleroderma Pulmonary Involvement
Scientific title: Low-Dose Oral Imatinib in the Treatment of Scleroderma Pulmonary Involvement: A Phase II Pilot Study
Date of first enrolment: February 2009
Target sample size: 30
Recruitment status: Recruiting
URL:  http://clinicaltrials.gov/show/NCT00573326
Study type:  Interventional
Study design:  Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment  
Phase:  Phase 2
Countries of recruitment
Italy
Contacts
Name:     Paolo Fraticelli, Dr
Address: 
Telephone: +390715964256
Email: p.fraticelli@ospedaliriuniti.marche.it
Affiliation: 
Name:     Paolo Fraticelli, Dr
Address: 
Telephone: +390715964256
Email: p.fraticelli@ospedaliriuniti.marche.it
Affiliation: 
Name:     Armando Gabrielli, MD
Address: 
Telephone:
Email:
Affiliation:  Università Politecnica delle Marche
Key inclusion & exclusion criteria

Inclusion Criteria:

- SSc with active pulmonary involvement refractory to conventional immunosuppressive
regimen

- Presence of active interstitial alveolitis (presence of grade 2 exertional dyspnea
according to Mahler Dyspnea Index AND worsening of lung function tests PLUS
interstitial alveolitis assessed by HRCTscan, ground-glass pattern involving at least
two lung segments OR dyspnea (as defined above)PLUS Interstitial alveolitis assessed
by HRCTscan (AS DEFINED ABOVE) AND neutrophilic or eosinophilic alveolitis detected
through broncoalveolar lavage

- Resistance to conventional immunosuppressive treatment (worsening or lack of
improvement of lung function tests after cyclophosphamide therapy, conducted for at
least three months, with a cumulative dosage > or = 6 g

- Age 18-80 years

- Ability ti give an informed consent

- Use of an acceptable method of birth control; pregnancy will be ruled out before
study beginning

Exclusion Criteria:

- Connective tissue diseases other than SSc

- Smoking Habit

- Pregnancy or lactation

- HBV or HCV infection

- Severe anaemia (Hb< or = 8g/dl)

- Hepatic disease (ALT or ALP>1.5 fold above normal levels)

- Moderate or severe renal failure (creatinine clearance<59ml/min)

- Severe heart failure, with ejection fraction < or = 35% measured by echocardiography

- thyroid disease with clinical evidence of hyperthyroidism treated with substitutive
therapy



Age minimum: 18 Years
Age maximum: 80 Years
Gender: Both
Health Condition(s) or Problem(s) studied
Systemic Sclerosis
Intervention(s)
Drug: Imatinib
Primary Outcome(s)
Improvement of the pulmonary interstitial disease, evaluated by spirometry and DLCO, lung HRCTscan, emogasanalysis. [Time Frame: 1 year]
Secondary Outcome(s)
Cutaneous Involvement, evaluated by the modified Rodnan skin score; quality of life and patient physical and emotional well being, evaluated by SF-36 score and HAQ [Time Frame: 1 year]
Secondary ID(s)
FARM 69J AJ9
EudraCT code:2007-005322-68
Source(s) of Monetary Support
Please refer to primary and secondary sponsors
Secondary Sponsor(s)
Università Politecnica delle Marche
Ethics review
Results
Results available:
Date Posted:
Date Completed:
URL:
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.6 - Version history Please fill this short user satisfaction survey